10-Q: Cingulate Inc. Reports First Quarter 2024 Results, Provides Update on Clinical Programs and Financial Position

Cingulate Inc. reported a net loss of $2.97 million for the first quarter of 2024, while also providing updates on its clinical programs and financial activities.

Summary

• Cingulate Inc. reported a net loss of $2.97 million for the first quarter of 2024, compared to a net loss of $4.0 million for the same period in 2023.
• The company's research and development expenses decreased to $1.8 million from $2.1 million year-over-year, while general and administrative expenses also decreased to $1.1 million from $1.7 million.
• Cingulate closed enrollment for its Phase 3 clinical trials for CTx-1301 and plans to submit a New Drug Application (NDA) in the first half of 2025.
• The company completed a formulation study for CTx-2103, showing a triple release of buspirone, and is planning a Pre-IND meeting with the FDA.
• Cingulate is seeking a strategic partnership for CTx-1301 and has a commercialization agreement with Indegene as a backup plan.
• The company raised $3.1 million through an At-the-Market offering and $7.5 million through a public offering in the first quarter of 2024.
• As of March 31, 2024, Cingulate had $1.1 million in cash and cash equivalents and believes it needs an additional $11-13 million to file the NDA for CTx-1301.
• The company has an accumulated deficit of $95.9 million as of March 31, 2024.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the ongoing losses, low cash position, and the need for significant additional funding. However, there are some positive aspects such as the progress in clinical trials and the reduction in operating expenses.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Operating expenses, including research and development and general and administrative costs, were reduced.
• Enrollment for the Phase 3 trials of CTx-1301 has been completed, moving the company closer to NDA submission.
• The formulation study for CTx-2103 showed promising results with a triple release of buspirone.
• The company successfully raised capital through both an At-the-Market offering and a public offering.
• The company has a commercialization agreement with Indegene as a backup plan if a strategic partnership is not secured.

Negatives

• The company continues to operate at a loss, with a net loss of $2.97 million for the quarter.
• Cingulate has an accumulated deficit of $95.9 million.
• The company needs an additional $11-13 million to file the NDA for CTx-1301, indicating a need for further capital raising.
• The company's cash and cash equivalents are low at $1.1 million, raising concerns about short-term liquidity.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is no guarantee that the company will be able to secure a strategic partnership for CTx-1301.
• The company's product candidates may not receive regulatory approval.
• The company may face challenges in commercializing its products even if they are approved.
• The company is subject to risks associated with any pre-clinical stage pharmaceutical company.
• The company operates in an environment of rapid technological change.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses in the near term. They plan to submit an NDA for CTx-1301 in the first half of 2025 and are seeking strategic partnerships. The company anticipates needing an additional $11-13 million to file the NDA for CTx-1301.

Management Comments

• Management is evaluating various strategies to obtain additional funding, which may include additional offerings of equity, issuance of debt, or other capital sources, including potential collaborations with other companies or other strategic transactions.
• Management believes that they can seek and win approval of CTx-2103 under the 505(b)(2) pathway, which typically requires less time and resources than the 505(b)(1) full NDA pathway.

Industry Context

Cingulate is operating in the competitive biopharmaceutical industry, focusing on treatments for ADHD and anxiety. The company's strategy of using a proprietary drug delivery platform and pursuing the 505(b)(2) regulatory pathway is aimed at reducing development time and costs. The company is also seeking strategic partnerships to leverage external resources for commercialization.

Comparison to Industry Standards

• Cingulate's approach of using a proprietary drug delivery platform is similar to other companies in the pharmaceutical industry that are focused on improving drug efficacy and patient compliance.
• The company's focus on the 505(b)(2) regulatory pathway is a common strategy for companies seeking to bring new formulations of existing drugs to market more quickly and cost-effectively, similar to companies like Supernus Pharmaceuticals and Tris Pharma.
• The need for additional capital is typical for pre-revenue biopharmaceutical companies, and Cingulate's situation is comparable to other companies in the sector that are in the clinical development stage, such as KemPharm and Neos Therapeutics.
• The company's net loss and cash burn are also typical for companies at this stage of development, and the need for additional funding is a common challenge in the industry.

Management Changes

Corporate Governance

Related Party Transactions

• The company had a related party note payable with Werth Family Investment Associates LLC (WFIA), which was converted to equity in two transactions.
• Peter Werth, manager of WFIA, is a member of the company's Board of Directors.

Stakeholder Impact

• Shareholders will experience dilution from the issuance of new shares.
• Employees may be affected by cost containment measures, including salary reductions.
• Customers (potential patients) may benefit from the development of new treatments for ADHD and anxiety.
• Suppliers and creditors may be impacted by the company's financial situation and need for additional funding.

Next Steps

• Submit a New Drug Application (NDA) for CTx-1301 in the first half of 2025.
• Conduct a Phase 1 food effect study utilizing CTx-1301's highest dosage strength, 50-mg.
• Request a Pre-IND meeting with the FDA to discuss the design of the clinical and regulatory program for CTx-2103.
• Initiate the clinical plan for CTx-1302 as soon as 2025, pending additional capital resources.
• Seek a strategic pharmaceutical partnership for CTx-1301.
• Continue to evaluate a wide array of strategic transactions as part of the plan to acquire or in-license and develop additional products and product candidates.

Key Dates

Keywords

biopharmaceutical, ADHD, CTx-1301, CTx-1302, CTx-2103, clinical trials, NDA, capital raise, drug delivery, pharmaceutical